BACKGROUND: The main aim of this study was to evaluate the expression and specific role of miR-33 in the progression of coronary heart disease (CAD), thereby evaluating their diagnostic ability and use in treatment in CAD patients. METHODS: Real time PCR was carried out to explore the level of miR-33 in the plasma of CAD patients and controls. ELISA was performed to analyze the level of placenta growth factor fragment (PLGF). Correlations between miR-33 and PLGF as well as other biochemical parameters were performed with Pearson's correlation analysis. RESULTS: First, we evaluated the level of plasma miR-33 in CAD patients and healthy controls. Compared with the control group, the level of plasma miR-33 was significantly increased in CAD patients. Furthermore, Spearman's correlation assay showed that plasma miR-33 positively correlated with the Gensini score (r = 0.354, p = 0.003). Meanwhile, plasma miR-33 was significantly enhanced in CAD patients with single- (1 ± 0.48), double- (1.85 ± 0.687), and triple-vessel disease (2.35 ± 0.87). In addition, Spearman's correlation assay demonstrated that plasma miR-33 positively correlated with plasma PLGF level (r = 0.354, p = 0.003). Lastly, ROC analysis showed that plasma miR-33 could screen CAD patients from healthy controls. CONCLUSIONS: In summary, we showed novel data that enhanced plasma miR-33 may promote the progression of CAD. Furthermore, plasma miR-33 could be used as a potential non-invasive biomarker for CAD patients, which may shed light on the diagnosis and therapy of CAD.
BACKGROUND: The main aim of this study was to evaluate the expression and specific role of miR-33 in the progression of coronary heart disease (CAD), thereby evaluating their diagnostic ability and use in treatment in CAD patients. METHODS: Real time PCR was carried out to explore the level of miR-33 in the plasma of CAD patients and controls. ELISA was performed to analyze the level of placenta growth factor fragment (PLGF). Correlations between miR-33 and PLGF as well as other biochemical parameters were performed with Pearson's correlation analysis. RESULTS: First, we evaluated the level of plasma miR-33 in CAD patients and healthy controls. Compared with the control group, the level of plasma miR-33 was significantly increased in CAD patients. Furthermore, Spearman's correlation assay showed that plasma miR-33 positively correlated with the Gensini score (r = 0.354, p = 0.003). Meanwhile, plasma miR-33 was significantly enhanced in CAD patients with single- (1 ± 0.48), double- (1.85 ± 0.687), and triple-vessel disease (2.35 ± 0.87). In addition, Spearman's correlation assay demonstrated that plasma miR-33 positively correlated with plasma PLGF level (r = 0.354, p = 0.003). Lastly, ROC analysis showed that plasma miR-33 could screen CAD patients from healthy controls. CONCLUSIONS: In summary, we showed novel data that enhanced plasma miR-33 may promote the progression of CAD. Furthermore, plasma miR-33 could be used as a potential non-invasive biomarker for CAD patients, which may shed light on the diagnosis and therapy of CAD.